Technical Analysis for ALGS - Aligos Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | -0.09% | |
| Earnings Movers | Other | -0.09% | |
| Wide Bands | Range Expansion | -0.09% | |
| Down 3 Days in a Row | Weakness | -0.09% | |
| Down 4 Days in a Row | Weakness | -0.09% | |
| 20 DMA Resistance | Bearish | -0.95% | |
| MACD Bullish Signal Line Cross | Bullish | -0.95% | |
| Earnings Movers | Other | -0.95% | |
| Outside Day | Range Expansion | -0.95% | |
| Wide Bands | Range Expansion | -0.95% |
| Alert | Time |
|---|---|
| 200 DMA Resistance | 11 minutes ago |
| 10 DMA Resistance | 11 minutes ago |
| Fell Below Previous Day's Low | 11 minutes ago |
| Down 2 % | 11 minutes ago |
| Down 1% | 11 minutes ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Alcohol Drug Development Coronavirus Hepatitis B Hepatitis Steatohepatitis Viruses Non Alcoholic Fatty Liver Disease Liver Disease Viral Disease Viral Infections Antiviral Therapies Chronic Hepatitis Viral Infection
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Alcohol Drug Development Coronavirus Hepatitis B Hepatitis Steatohepatitis Viruses Non Alcoholic Fatty Liver Disease Liver Disease Viral Disease Viral Infections Antiviral Therapies Chronic Hepatitis Viral Infection
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.34 |
| 52 Week Low | 0.54 |
| Average Volume | 364,645 |
| 200-Day Moving Average | 0.79 |
| 50-Day Moving Average | 0.91 |
| 20-Day Moving Average | 0.82 |
| 10-Day Moving Average | 0.79 |
| Average True Range | 0.07 |
| RSI (14) | 42.53 |
| ADX | 17.29 |
| +DI | 16.53 |
| -DI | 19.42 |
| Chandelier Exit (Long, 3 ATRs) | 0.88 |
| Chandelier Exit (Short, 3 ATRs) | 0.94 |
| Upper Bollinger Bands | 0.98 |
| Lower Bollinger Band | 0.67 |
| Percent B (%b) | 0.37 |
| BandWidth | 37.62 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.03 |
| MACD Histogram | 0.0003 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.86 | ||||
| Resistance 3 (R3) | 0.87 | 0.84 | 0.85 | ||
| Resistance 2 (R2) | 0.84 | 0.82 | 0.84 | 0.85 | |
| Resistance 1 (R1) | 0.81 | 0.81 | 0.80 | 0.81 | 0.84 |
| Pivot Point | 0.79 | 0.79 | 0.78 | 0.79 | 0.79 |
| Support 1 (S1) | 0.76 | 0.77 | 0.75 | 0.76 | 0.73 |
| Support 2 (S2) | 0.74 | 0.76 | 0.74 | 0.72 | |
| Support 3 (S3) | 0.71 | 0.74 | 0.72 | ||
| Support 4 (S4) | 0.70 |
